Vivo Bio Tech Limited has announced its Unaudited Standalone and Consolidated Financial Results for the second quarter and half-year ended September 30, 2026. The company reported a standalone net profit of ₹66.28 lakh for the quarter, with diluted earnings per share at ₹0.30. Consolidated net profit stood at ₹66.28 lakh for the same period.
Financial Performance for Q2 FY27
Vivo Bio Tech Limited disclosed its financial results for the second quarter and half-year ended September 30, 2026. The Board of Directors reviewed and approved these unaudited results on November 11, 2026.
Standalone Results
For the second quarter ended September 30, 2026, Vivo Bio Tech reported a standalone profit before tax of ₹136.67 lakh. After accounting for a tax expense of ₹70.40 lakh, the standalone net profit after tax stood at ₹66.28 lakh.
The standalone earnings per equity share (basic and diluted) for the quarter were ₹0.30.
Consolidated Results
On a consolidated basis, the company reported a profit before tax of ₹136.67 lakh for the second quarter ended September 30, 2026. The consolidated tax expense was ₹70.40 lakh, resulting in a consolidated net profit after tax of ₹66.28 lakh.
Consolidated earnings per equity share (basic and diluted) for the quarter were also ₹0.30.
Half-Yearly Performance
For the half-year ended September 30, 2026, the standalone profit before tax was ₹170.20 lakh, with a net profit after tax of ₹84.71 lakh. The standalone earnings per equity share for the half-year were ₹0.38.
The consolidated profit before tax for the half-year was ₹220.82 lakh, with a net profit after tax of ₹128.97 lakh. Consolidated earnings per equity share for the half-year were ₹0.58.
The company also provided comparative figures for the previous financial periods as required by SEBI regulations.
Source: BSE
